RPL17 and hepatocellular carcinoma: Based on the study of RGS16 in oncology, we found that there are still new research advances in PATHOLOGY and SURGERY, mainly including signature, PD 1,[59] bone calcium, histone deacetylase inhibitor, gene signature, gemcitabine,[59] hepatocellular carcinoma,[61] and pancreatic ductal adenocarcinoma.